
Rockwell Medical (RMTI) Stock Forecast & Price Target
Rockwell Medical (RMTI) Analyst Ratings
Bulls say
Rockwell Medical Inc. is expected to generate upwards of $10 million in net sales during the first year of a recent agreement, contributing to revenue that was not previously accounted for in projections for 2025, and will benefit from incremental price increases in subsequent years. The company is actively working to address reduced volume demand from its largest customer by pursuing new, higher-margin customer contracts and diversifying its product offerings, with several opportunities already in late-stage negotiations. Furthermore, a partnership with HydroCare for the installation of dry acid concentrate mix systems aims to enhance sales and strengthen Rockwell's position within the dialysis market.
Bears say
Rockwell Medical's outlook has been negatively impacted by a projected decline in net sales of approximately $31 million to $38 million in 2025, as its largest customer intends to reduce volumes due to a diversification of its supplier base. The company's financial forecasts have been adjusted, reflecting an anticipated revenue decrease from $107.3 million in 2025 to $87.6 million, primarily due to the loss of product volumes tied to this key customer. Additionally, historical profit margins associated with this customer's purchases have been poor, ranging from gross losses to single-digit gross margins, further contributing to the negative sentiment surrounding Rockwell Medical's financial stability.
This aggregate rating is based on analysts' research of Rockwell Medical and is not a guaranteed prediction by Public.com or investment advice.
Rockwell Medical (RMTI) Analyst Forecast & Price Prediction
Start investing in Rockwell Medical (RMTI)
Order type
Buy in
Order amount
Est. shares
0 shares